Stemline Therapeutics Inc (STML) Received Purchase Rating at Cowen and Company

Stemline Therapeutics Inc (STML) Received Purchase Rating at Cowen and Company

Cowen and Company reiterated their buy rating on shares of Stemline Therapeutics Inc (NASDAQ:STML) in a report released on Thursday.

“STML announced that it has completed enrollment of SL-401’s pivotal study in BPDCN.”,” Cowen and Company’s analyst wrote.

STML has been the topic of several other research reports. HC Wainwright restated a buy rating and issued a $34.00 target price on shares of Stemline Therapeutics in a research note on Monday. Roth Capital restated a buy rating and issued a $32.00 target price on shares of Stemline Therapeutics in a research note on Wednesday, December 7th. Wedbush restated an outperform rating and issued a $15.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, December 6th. Ladenburg Thalmann Financial Services set a $41.00 target price on Stemline Therapeutics and gave the company a buy rating in a research note on Monday. Finally, Zacks Investment Research cut Stemline Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 18th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $24.33.

Stemline Therapeutics (NASDAQ:STML) traded up 0.59% during midday trading on Thursday, hitting $8.55. The stock had a trading volume of 42,781 shares. The firm’s market capitalization is $153.48 million. The firm has a 50-day moving average price of $7.79 and a 200-day moving average price of $10.60. Stemline Therapeutics has a 1-year low of $4.06 and a 1-year high of $14.60.

In other Stemline Therapeutics news, insider David Gionco sold 6,486 shares of the business’s stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total transaction of $45,337.14. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Kenneth Hoberman sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $6.97, for a total value of $27,880.00. The disclosure for this sale can be found here. Insiders have sold a total of 65,356 shares of company stock worth $531,879 in the last ninety days. Insiders own 16.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in Stemline Therapeutics during the third quarter valued at $400,000. State Treasurer State of Michigan bought a new position in Stemline Therapeutics during the third quarter valued at $217,000. Oak Ridge Investments LLC raised its position in Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 2,663 shares during the period. Columbus Circle Investors bought a new position in Stemline Therapeutics during the third quarter valued at $1,577,000. Finally, Baker BROS. Advisors LP bought a new position in Stemline Therapeutics during the third quarter valued at $3,612,000. 37.76% of the stock is currently owned by hedge funds and other institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Related posts

Leave a Comment